Compare BKSY & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKSY | SGP |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.0M | 799.4M |
| IPO Year | 2019 | 2026 |
| Metric | BKSY | SGP |
|---|---|---|
| Price | $20.82 | $24.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $38.42 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 826.6K | 108.2K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.92 | N/A |
| Revenue Next Year | $36.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.41 | $17.06 |
| 52 Week High | $52.88 | $30.56 |
| Indicator | BKSY | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 43.98 |
| Support Level | $20.40 | $25.00 |
| Resistance Level | $24.34 | $26.29 |
| Average True Range (ATR) | 1.21 | 1.42 |
| MACD | 0.03 | -0.41 |
| Stochastic Oscillator | 16.71 | 30.19 |
BlackSky Technology Inc is a space-based technology company that delivers real-time imagery, analytics and high-frequency monitoring of the worlds critical and strategic locations, economic assets, and events. By taking a software-first technology approach, Company is delivering real-time space-based intelligence at disruptive speed, scale and economics. Companies single operating and reportable segment, provided space-based intelligence products and services through three integrated revenue streams-space-based intelligence & AI services, mission solutions, and technology programs. Geographically, the company operates in United States and Rest of world.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.